Key facts today
697.888 ARS
341.86 B ARS
2.77 T ARS
About Biogen Inc.
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Founded
1978
ISIN
ARBCOM4601A8
FIGI
BBG00PCCBPX0
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
$BIIB imploding to the downsideStock is leaking out lows, next stop 182.23 where we should bounce. Until then i am #bearish
BIIB Long, Coming Soon!The price has sold off from the $207.59 pivot level, dropping to $193.84 as of the Monday, September 30th close. The sharp decline from $200 to $190 over two days last week was largely due to sector-wide weakness, as reflected in the IBB (Biotech ETF). Since then, both the ETF and BIIB have been con
BIIB - Breakout soonBIIB is forming a tight pennant setup. Either this gonna breakout here and rally or Fakeout and crash. Let’s see..!
Long anywhere here.
Target #1 - 250
Target #2 - 260
Target #3 - 275
Stop loss - 225
BIIB bear trend breakout? BIIB has broken a long running bearish trend since Jan 2023
Entry @ 223
TP1 @ 255
SL @ 200
Fundamentally strong stock hence the far off Stop loss but still a 1:2 ratio risk reward
Biogen Stock Surge 4.85% on Approval For ALS DrugBiogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical need
Legendary Sharkley A combination of a Shark harmonic pattern and a Gartley has emerged at the pattern completion zone. There is also bullish divergence on the RSI at the comfirmation double bottom. NASDAQ:BIIB has been oscillating between around $190-$440 since 2013 and seems to be at a good bargain price of $218 cu
9 year consolidation about over?Might make this one a core position over the coming months... 200 month moving average tested successfully once already.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where BIIB is featured.
